== Serological changes according to earlier response to HBV vaccines:(A)median regular monthly anti-S(RBD) antibody levels,(B)Proportion of patients with effective humoral response after vaccination according to response to HBV vaccine. == Decrease in Anti-S(RBD) Antibody Levels Before and After the Third mRNA Vaccine Dose == After a median follow-up of 4 months after the second dose of mRNA vaccine, there was a mean monthly decrease in anti-S(RBD) antibodies of 33 14.5%. weeks. The mean regular monthly rate of antibody titer decrease decreased from 33 14.5 to 25 16.7%. Multivariate regression analysis showed that earlier exposure to COVID-19 and response to HBV vaccines were associated with an effective sustained humoral immune response. == Summary == Immunization with SARS-CoV-2 mRNA vaccines elicits an effective immediate humoral immune response in hemodialysis individuals, with a progressive waning in antibody levels. A third booster dose enhances the immune response with significantly higher antibody levels and more sustained humoral immune response. COVID-nave individuals and individuals without earlier response to HBV vaccines are likely to benefit from receiving more booster doses to PF-06263276 maintain an effective immune response. Keywords:COVID-19, chronic kidney disease, immunology, vaccine, prevention == Intro == Individuals on hemodialysis (HD) have an increased incidence of illness with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the general human population, and when infected their mortality risk is definitely higher (13). For these reasons, HD individuals PF-06263276 have been included as one of the priority organizations in vaccination programs (4,5). This practice has been carried out despite the fact that chronic kidney disease individuals have been excluded from the main studies on vaccination (68) and that their immune response to vaccination against additional viruses is less effective than in the general human population (9). You will find no specific recommendations concerning the most adequate vaccine routine for HD individuals. Around 90% of HD PF-06263276 individuals without previous illness with SARS-CoV-2 develop an immediate humoral and cellular immune response after the administration of two doses of mRNA vaccines (10,11). Despite these results, there is a reported mortality of 11% in HD individuals who get infected with COVID-19 after receiving the two mRNA vaccine doses (12). This elevated mortality can be attributed to different factors: a lower and less effective immunological response compared to the general human population (13,14) as well as a progressive decrease in antibody levels (15). For these reasons, the administration of a third SARS-CoV-2 mRNA vaccine dose has been recommended (12,16,17). You will find no longitudinal studies concerning SARS-CoV-2 vaccine-induced immune responses for more than 4 weeks after receiving the third mRNA vaccine dose in individuals on HD, which are needed to optimize Unc5b medical care and strategy preventive strategies with this human population. In this study, we describe the serological regular monthly changes against SARS-CoV-2 in HD individuals after 1 year of follow-up from an initial immunization with two doses of mRNA vaccines. A third booster dose was given after 5 weeks from the second dose, with continuous regular monthly serological assessment for 4 weeks following a third vaccine dose. We aimed to describe the factors associated with a sustained humoral response and determine the group of individuals who are more likely to benefit from receiving a third booster dose. == Materials and Methods == == Study Design and Human population == We designed an observational, longitudinal study to evaluate the immune response induced by the different mRNA vaccines against SARS-CoV-2 in individuals going to two HD devices: an in-center hospital dialysis unit and its affiliated satellite dialysis unit. The study comprised all HD individuals who received vaccination against SARS-CoV-2 PF-06263276 having a two-dose mRNA vaccine between December 28th 2020 and June 30th 2021, either BNT162b2 (BionTech/Pfizer) or mRNA-1273 (Moderna), given according to the manufacturers recommendations. The type of vaccine was assigned according to the available vaccines at the local vaccination point or at our center. Individuals were classified as having experienced a previous COVID-19 illness if there was clear medical paperwork having a positive SARS-CoV-2 PCR swab or in presence of nucleocapsid-IgG specific PF-06263276 antibodies in serological analyses before the administration of the 1st dose of the vaccine. Individuals who experienced received the vaccination routine before starting HD, individuals with an unfamiliar serological status for SARS-CoV-2 before vaccination and individuals who either received an adenoviral vector-based vaccine or did not complete the full SARS-CoV-2 mRNA vaccine routine were excluded from the study. The study was conducted according to the guidelines of the Declaration of Helsinki and received the authorization of the Honest Committee for Clinical Investigation.